SCHEMBL3582693

SCHEMBL3582693

CNc1cc(-n2nc(C)cc2Nc2cc(NC(=O)c3cc(-n4cnc(C)c4)cc(C(F)(F)F)c3)ccc2C)ncn1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 2/20 0.58
KDM4E B2RXH2 1/20 0.56
POLB P06746 1/20 0.56
RECQL P46063 1/20 0.56
MAP4K2 Q12851 1/20 0.56
MAPT P10636 1/20 0.53
SRC P12931 4/20 0.51
LCK P06239 3/20 0.51
LYN P07948 3/20 0.51
HCK P08631 3/20 0.51
KDR P35968 2/20 0.51
INSR P06213 1/20 0.51
BRAF P15056 5/20 0.49
RAF1 P04049 5/20 0.49
NR2E1 Q9Y466 1/20 0.49
ABL1 P00519 8/20 0.48
BCR P11274 4/20 0.48
EPHB2 P29323 2/20 0.48
LDLR P01130 2/20 0.47
PDGFRB P09619 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3580903 0.91 MAP4K2 (0.65) CSF1RMAP4K2SRCLCKLYN
SCHEMBL3592374 0.91 MAP4K2 (0.55) CSF1RKDM4EPOLBRECQLMAP4K2
SCHEMBL3591858 0.87 LCK (0.45) SRCLCKLYNHCKKDR
SCHEMBL3588042 0.87 LYN (0.50) CSF1RKDM4EPOLBRECQLMAP4K2
SCHEMBL3582783 0.87 LCK (0.46) CSF1RSRCLCKLYNHCK
SCHEMBL3589623 0.86 LYN (0.59) CSF1RMAP4K2SRCLCKLYN
SCHEMBL1827777 0.86 CSF1R (0.60) CSF1RKDM4EPOLBRECQLMAP4K2
SCHEMBL3590781 0.86 CSF1R (0.58) CSF1RSRCLCKLYNHCK
SCHEMBL3592421 0.85 CSF1R (0.58) CSF1RKDM4EPOLBRECQLMAP4K2
SCHEMBL3591813 0.85 LYN (0.51) CSF1RKDM4EPOLBRECQLMAP4K2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8202876-B2 Compounds and compositions as protein kinase inhibitors IRM LLC (BM) 2012-06-19 US claimed
US-20100029605-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2010-02-04 US claimed
US-8202876-B2 Compounds and compositions as protein kinase inhibitors IRM LLC (BM) 2012-06-19 US disclosed
US-8202876-B2 Compounds and compositions as protein kinase inhibitors IRM LLC (BM) 2012-06-19 US disclosed
US-20100029605-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2010-02-04 US disclosed
US-20100029605-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2010-02-04 US disclosed
WO-2008042639-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2008-04-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029605-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS FYN, ABL2, LCK CSF1R 476/4885KDM4E 1894/4885POLB 2427/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.